Locations:
Search IconSearch
October 8, 2021/Cancer

Stereotactic Radiosurgery for Brain Metastases (Podcast)

Why it remains the mainstay for newly diagnosed metastases and tumors

Cleveland Clinic Cancer Advances · Stereotactic Radiosurgery in the Treatment Landscape for Brain Metastases

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Brain metastases are about 10 times more common than primary brain tumors in adults, so it is really important that medical oncologists and primary care doctors are tuned into the possibility of their patients with cancer developing brain metastases,” says neurosurgeon Gene Barnett, MD, MBA, Director of Cleveland Clinic’s Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center. “The treatment options are better if we get to these metastases when they are smaller and/or asymptomatic.”

One treatment option is stereotactic radiosurgery, a minimally invasive intervention that uses targeted radiation beams to treat brain tumors and other abnormalities. In a recent episode of Cleveland Clinic’s Cancer Advances podcast, Dr. Barnett discusses the evolution of traditional surgical approaches for treating patients with brain metastases and the ability of stereotactic radiosurgery to deliver superior outcomes. He provides insight on the following:

  • Presenting symptoms of brain metastases
  • The range of treatment options, from surgical interventions to medication and radiation therapies
  • A step-by-step look at the stereotactic radiosurgery procedure
  • The emergence and promising results of neoadjuvant stereotactic surgery
  • The importance of combining systemic therapies with radiosurgery for tumor control

Click the podcast player above to listen to the episode now, or read on for a short edited excerpt.

Excerpt from the podcast

Podcast host Dale Shepard, MD, PhD: What does [stereotactic radiosurgery] look like from a patient perspective, in terms of what their experience is as they undergo the treatment and how well they’re likely to do? When I see patients in clinic and I tell them they have a lung met or a liver met, they’re not nearly as frightened as when I tell them they have a brain met. So how do we reassure patients?

Advertisement

Dr. Barnett: Well, I think that’s totally understandable because people understand the brain is who we are and allows us to do what we want to do. Many people know, or know of, people who have had brain tumors and have not done well. I think the point of reassurance is that we can actually do a really good job of controlling brain metastases these days with radiosurgery, to the extent that most people who have brain metastases don’t die from them — rather, they die of their systemic disease and their brain disease is under control. For the vast majority of brain metastases, the control rate is upwards of 90% to 95%. And with the staged technique, the control is typically durable. So, I think that giving patients the facts should be consoling. You don’t want to sugarcoat things, but the facts are that the outcome is actually probably a lot better than what they were thinking.

Advertisement

Related Articles

Hands after RT
January 30, 2026/Cancer/Radiation Oncology
Patient Case Study: Radiation Therapy Used to Treat Dupuytren's Disease

Radiation therapy helped shrink hand nodules and improve functionality

Dr. Ali and patient
January 29, 2026/Cancer/News & Insight
Real-World Data Reveals Gap Between Guidelines and Practice in HER2+ Breast Cancer Care

Standard of care is linked to better outcomes, but disease recurrence and other risk factors often drive alternative approaches

Dr. Thomas Budd
January 28, 2026/Cancer/Innovations
Breast Cancer Vaccine Moves One Step Forward

Phase 1 study demonstrates immune response in three quarters of patients with triple-negative breast cancer

Dr. Mukhejee and colleagues
January 22, 2026/Cancer/News & Insight
Rare Cancers and Blood Disease Program Accelerates Diagnostic Journey

Multidisciplinary teams bring pathological and clinical expertise

genetic test
January 16, 2026/Cancer/News & Insight
Five Percent of U.S. Population Carries Pathogenic Variants Associated with Cancer Risk

Genetic variants exist irrespective of family history or other contributing factors

GLP-1
January 12, 2026/Cancer/Blood Cancers
GLP-1a Therapy Improves Survival in Patients with Polycythemia Vera and Myelodysplastic Syndromes

Study shows significantly reduced risk of mortality and disease complications in patients receiving GLP-1 agonists

Oncology nurse
January 9, 2026/Cancer
Improving Patient Experience in Inpatient Hematology: A Nursing Perspective

Structured interventions enhance sleep, safety and caregiver resiliency in high-acuity units

PET scan
January 7, 2026/Cancer/Blood Cancers
Case Study: 21-Year-Old Patient with Refractory T-Cell Lymphoma

Addressing rare disease and challenging treatment course in an active young patient

Ad